CompoAtlas

RenewGlow

On sale on the US market (according to the DSLD)

Skin Research Institute, food supplement from the US market

RenewGlow (Skin Research Institute), a food supplement without a usable barcode in DSLD, is described by its US market label. If sold in France, it would be subject to 6 points of French or European regulation, detailed below. The formula sold in Europe under the same name may differ.

Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.

Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.

If this product were sold in France

A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.

Label composition

Brand
Skin Research Institute
Barcode
Not provided or invalid in DSLD
Form
Tablet
One serving
2 tablets
Servings
up to 1 serving per day
Other ingredients (in English, as written)
Dicalcium Phosphate, Stearic Acid, Croscarmellose Sodium, Water, Purified, Hydroxypropyl Methylcellulose, Glycerin, Peppermint Oil, Magnesium Stearate, Silicon Dioxide, Microcrystalline Cellulose
Ingredient (as written, in English)CategoryPer serving
Vitamin CVitamin400 mg
Vitamin EVitamin40 mg
Vitamin B6Vitamin4 mg
BiotinVitamin5,000 µg
Pantothenic AcidVitamin20 mg
CalciumMineral85 mg
ZincMineral20 mg
SeleniumMineral140 µg
CopperMineral1 mg
ManganeseMineral4 mg
OptiMSMOther substance500 mg
SilicaMineral12.5 mg
L-MethionineAmino acid125 mg
Citrus Bioflavonoid ComplexOther substance100 mg
Hyaluronic AcidOther substance5 mg
Alpha-Lipoic AcidOther substance50 mg
Proprietary BlendBlend417 mg
Gotu Kola Aerial Parts Extract (Centella asiatica)Plantnot stated
Grape Seed Inner Core ExtractPlantnot stated
Fo-Ti, Powder (Reynoutria multiflora)Plantnot stated
Amla Fruit Extract (Phyllanthus emblica)Plantnot stated
Para-Aminobenzoic AcidOther substancenot stated
Goji Berry Fruit ExtractPlantnot stated
Bladderwrack, Powder (Fucus vesiculosus)Plantnot stated
Nori yaki (Porphyra umbilicalis)Plantnot stated
Wakame powder (Undaria pinnatifida)Plantnot stated
Olive Water Fruit ExtractPlantnot stated
Astaxanthin Complex, NaturalBlendnot stated

Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.

Other versions of this label

The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.

This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Amla Fruit Extract
    Read the warning, when it applies and the studies cited

    Amla - Phyllanthus Emblica

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (HC 2009).

    Sources cited by Health Canada (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Applies to products providing more than 3 grams of amla, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (HC 2009).

    Sources cited by Health Canada (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Condition of application: Amlapitta, Digestive tonic.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: Laxative.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (HC 2009; Pray 2006; CPhA 2002).

    Sources cited by Health Canada (3)
    • CPhA 2002: Repchinsky C, editor-in-chief. Patient Self-Care: Helping Patients Make Therapeutic Choices. 1st edition. Ottawa (ON): Canadian Pharmacists Association; 2002.
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
    • Pray WS. Non-Prescription Product Therapeutics. 2nd edition. New York (NY): Lippincott Williams & Wilkins; 2006.

    Contraindications

    Condition of application: Laxative.

    Do not use if you have fever or any undiagnosed gastrointestinal trouble (HC 2009).

    Sources cited by Health Canada (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Known adverse reactions

    Condition of application: Amlapitta, Antioxidant, Digestive tonic, Rasayana or Eye tonic.

    When using this product you may experience a laxative effect.

    Health Canada monograph dated 28 March 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).

Has the product changed? Photograph the packaging.

Brand : Skin Research Institute

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “RenewGlow (Skin Research Institute): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/dsld-321846-renewglow-skin-research-institute, updated 23 January 2025.

Enter to analyse, Shift+Enter for a new line